$265 Million is the total value of Octagon Capital Advisors LP's 28 reported holdings in Q1 2021. The portfolio turnover from Q4 2020 to Q1 2021 was 54.8% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| IMAB | Buy | I MABsponsored ads | $25,692,000 | +19.9% | 530,050 | +16.6% | 9.68% | +30.3% |
| CRIS | Sell | CURIS INC | $24,093,000 | +33.7% | 2,128,400 | -3.3% | 9.08% | +45.3% |
| APLS | APELLIS PHARMACEUTICALS INC | $23,531,000 | -25.0% | 548,374 | 0.0% | 8.86% | -18.5% | |
| FDMT | Buy | 4D MOLECULAR THERAPEUTICS IN | $16,410,000 | +4.8% | 378,288 | +0.1% | 6.18% | +13.9% |
| XLRN | ACCELERON PHARMA INC | $15,238,000 | +6.0% | 112,363 | 0.0% | 5.74% | +15.2% | |
| GOSS | Sell | GOSSAMER BIO INC | $13,072,000 | -13.5% | 1,413,138 | -9.6% | 4.92% | -6.0% |
| ARVN | ARVINAS INC | $11,799,000 | -22.2% | 178,500 | 0.0% | 4.44% | -15.4% | |
| CLDX | Sell | CELLDEX THERAPEUTICS INC NEW | $11,565,000 | -36.6% | 561,398 | -46.1% | 4.36% | -31.1% |
| IKNA | New | IKENA ONCOLOGY INC | $11,300,000 | – | 400,000 | +100.0% | 4.26% | – |
| RCUS | Buy | ARCUS BIOSCIENCES INC | $11,232,000 | +44.2% | 400,000 | +33.3% | 4.23% | +56.7% |
| RNA | Buy | AVIDITY BIOSCIENCES INC | $9,741,000 | -11.2% | 446,641 | +3.9% | 3.67% | -3.6% |
| DYN | Buy | DYNE THERAPEUTICS INC | $9,064,000 | -10.4% | 583,649 | +21.2% | 3.41% | -2.6% |
| PMVP | PMV PHARMACEUTICALS INC | $8,223,000 | -46.5% | 250,000 | 0.0% | 3.10% | -41.9% | |
| CCXI | Sell | CHEMOCENTRYX INC | $7,690,000 | -44.8% | 150,076 | -33.3% | 2.90% | -40.0% |
| DSGN | New | DESIGN THERAPEUTICS INC | $7,475,000 | – | 250,000 | +100.0% | 2.82% | – |
| CNTB | New | CONNECT BIOPHARMA HLDGS LTDads | $6,910,000 | – | 373,492 | +100.0% | 2.60% | – |
| TSHA | TAYSHA GENE THERAPIES INC | $6,505,000 | -23.5% | 320,440 | 0.0% | 2.45% | -16.9% | |
| CRDF | CARDIFF ONCOLOGY INC | $6,019,000 | -48.5% | 650,000 | 0.0% | 2.27% | -44.1% | |
| NGM | Buy | NGM BIOPHARMACEUTICALS INC | $5,814,000 | +155.1% | 200,000 | +165.9% | 2.19% | +177.2% |
| RVMD | REVOLUTION MEDICINES INC | $5,787,000 | +15.9% | 126,136 | 0.0% | 2.18% | +25.9% | |
| KRON | KRONOS BIO INC | $4,278,000 | -2.0% | 146,173 | 0.0% | 1.61% | +6.5% | |
| ISEE | IVERIC BIO INC | $4,203,000 | -10.6% | 680,036 | 0.0% | 1.58% | -2.8% | |
| MRUS | New | MERUS N V | $4,178,000 | – | 200,000 | +100.0% | 1.57% | – |
| HLXA | HELIX ACQUISITION CORP | $4,080,000 | -10.3% | 400,000 | 0.0% | 1.54% | -2.5% | |
| EWTX | New | EDGEWISE THERAPEUTICS INC | $4,063,000 | – | 125,000 | +100.0% | 1.53% | – |
| RXDX | New | PROMETHEUS BIOSCIENCES INC | $3,652,000 | – | 200,000 | +100.0% | 1.38% | – |
| JYAC | JIYA ACQUISITION CORP | $2,952,000 | -4.5% | 300,000 | 0.0% | 1.11% | +3.8% | |
| FHTX | New | FOGHORN THERAPEUTICS INC | $911,000 | – | 69,132 | +100.0% | 0.34% | – |
| AXSM | Exit | AXSOME THERAPEUTICS INC | $0 | – | -20,000 | -100.0% | -0.56% | – |
| KDMN | Exit | KADMON HLDGS INC | $0 | – | -434,114 | -100.0% | -0.62% | – |
| ACRS | Exit | ACLARIS THERAPEUTICS INC | $0 | – | -350,000 | -100.0% | -0.78% | – |
| ARQT | Exit | ARCUTIS BIOTHERAPEUTICS INC | $0 | – | -100,000 | -100.0% | -0.98% | – |
| IVA | Exit | INVENTIVA SAads | $0 | – | -200,000 | -100.0% | -1.00% | – |
| VIE | Exit | VIELA BIO INC | $0 | – | -85,409 | -100.0% | -1.06% | – |
| KURA | Exit | KURA ONCOLOGY INC | $0 | – | -150,000 | -100.0% | -1.70% | – |
| KNSA | Exit | KINIKSA PHARMACEUTICALS LTD | $0 | – | -295,238 | -100.0% | -1.81% | – |
| FGEN | Exit | FIBROGEN INC | $0 | – | -146,014 | -100.0% | -1.88% | – |
| CALT | Exit | CALLIDITAS THERAPEUTICS ABsponsered ads | $0 | – | -200,000 | -100.0% | -2.33% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2021-05-17
Signatures
The EDGAR filing(s) were signed by:
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| APELLIS PHARMACEUTICALS INC | 12 | Q3 2023 | 33.2% |
| ARCUS BIOSCIENCES INC | 12 | Q3 2023 | 18.1% |
| CELLDEX THERAPEUTICS INC NEW | 12 | Q3 2023 | 10.1% |
| GOSSAMER BIO INC | 12 | Q3 2023 | 6.2% |
| 4D MOLECULAR THERAPEUTICS IN | 10 | Q1 2023 | 6.6% |
| BRIDGEBIO PHARMA INC | 10 | Q3 2023 | 6.6% |
| AVIDITY BIOSCIENCES INC | 10 | Q1 2023 | 3.8% |
| VERA THERAPEUTICS INC | 9 | Q2 2023 | 3.5% |
| DYNE THERAPEUTICS INC | 9 | Q3 2023 | 3.5% |
| STOKE THERAPEUTICS INC | 9 | Q2 2023 | 3.7% |
View Octagon Capital Advisors LP's complete holdings history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2024-02-14 |
| SC 13G/A | 2024-02-06 |
| SC 13G/A | 2024-02-05 |
| SC 13G | 2024-02-05 |
| 13F-HR | 2023-11-14 |
| 13F-HR | 2023-08-14 |
| 13F-HR | 2023-05-15 |
| 13F-HR | 2023-02-14 |
| SC 13G | 2023-01-25 |
| 13F-HR | 2022-11-14 |
View Octagon Capital Advisors LP's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.